Brutalist Biotech
Max
3
|
5
|
10
|
20
items per feed.
Cutting-edge Biotech news: Presented the old-fashioned way.
Fierce Biotech
Trump's FDA pick Heidi Overton calls vaccines, mifepristone safe and effective in confirmation hearing
(1d)
China’s Henlius carves out $440M T-cell engager deal with Amberstone
(1d)
Acadia misses mark in Alzheimer’s but concludes phase 3 ‘absolutely worth’ pursuing
(1d)
Merck sees pivotal victory for $3B eye disease prospect
(1d)
Roche pens backloaded $2B deal with Atavistik to discover allosteric CVRM drugs
(1d)
Adagio Medical kicks off strategic review, trims more than half its staff
(1d)
Lilly puts up $100M, plus billions on the backend, to form 5-target deal with InnoCare
(1d)
Grail survives adcomm vote as it awaits FDA decision for cancer blood test
(1d)
Kyverna ‘resetting conversation’ with 1-year miv-cel data as autoimmune CAR-T peers hit safety snags
(2d)
Trump's Department of War bets $47M on Flagship biotechs to develop countermeasures
(2d)
BioPharma Dive
This week in charts: Novo’s rise and fall and AI biotechs’ big haul
(7h)
Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data
(10h)
RNAi drug specialist ADARx raises $446M IPO
(23h)
Grail multicancer detection test wins FDA advisers’ backing
(1d)
FDA nominee Overton parries vaccine questions at Senate hearing
(1d)
Merck reveals study success, and possible safety worries, for eye drug hopeful
(1d)
Lilly’s latest China drug deal; Immunovant’s setback in lupus
(1d)
Enveda, an AI drugmaker, banks $311M in venture funding
(2d)
Roche, Ionis RNA drug scores in kidney disease study
(2d)
9 pharma leaders sound ‘alarm bells’ on biotech’s decline in Europe
(2d)
Endpoints News
FDA approves Mirum’s drug for ultra-rare soft tissue disease
(4h)
Jury awards Nektar $90M in suit against Lilly
(6h)
Pharma industry asks FDA for more details on when one trial is enough
(7h)
To get drugmakers into ultra-rare disease, the answer isn’t rare disease at all
(8h)
Legend's five-year data suggests Carvykti could be a cure; Addex, Indivior split
(9h)
Endpoints 11 2026 winner Kali looked at China for pipeline drugs, then turned in-house
(9h)
Endpoints 11 2026 winner Azalea melds gene editing and CAR-T
(9h)
Endpoints 11 2026 winner NewLimit searches for a new class of anti-aging drugs
(9h)
Endpoints 11 2026 winner Anew Labs offers a China-based rival to AI labs
(9h)
Endpoints 11 2026 winner Stipple Bio is taking precision to the next level
(9h)
BioSpace
After COVID, biomanufacturing tackles preparedness and commercialization challenges
(9h)
Nektar prevails in legal battle with Lilly over broken rezpeg partnership
(9h)
ADARx raises $446M in biotech’s third largest IPO of 2026, City files to go public
(10h)
J&J, Legend tout long-term survival benefits for Carvykti in multiple myeloma
(10h)
Genentech makes $1.5B+ deal with AI heavyweight Earendil for cancer bispecifics
(11h)
FDA slams GLP-1 compounder over risk of contaminating drugs ‘with filth’
(1d)
US senators grill FDA nominee Overton on ability to ‘stand up’ to Trump
(1d)
Acadia slides on Phase 2 miss in Alzheimer’s psychosis but keeps moving asset forward
(1d)
Merck’s experimental eye drug matches Roche’s VEGF inhibitor but safety concerns emerge
(1d)
Kyverna steps closer to FDA-first CAR T for an autoimmune condition with durability data
(1d)
STAT News
Licensing deals on generic versions of Roche flu drug aimed at preparing for pandemic
(6h)
Lilly wins approval for once-weekly insulin shot
(8h)
FDA commissioner nominee Heidi Overton is ignoring the science on abortion drug
(9h)
Up and down the ladder: The latest comings and goings
(10h)
We’re reading about a reticent FDA commish nominee, a Novo deal, and more
(10h)
Federal judge rolls back landmark disability protections
(11h)
How Big Tobacco flooded the FDA with public comments to kill a menthol cigarette ban
(15h)
At least five candidates vie to become the next WHO leader, as questions over U.S. role loom
(15h)
The head of Kennedy’s new autism project served in Iraq War, worked with Sesame Street
(15h)
RFK Jr.’s use of the National Center for Health Statistics will add confusion to measles deaths count
(15h)
BioPharma Trend
AI Drug Discovery Startups Raise $526 Million in Two Days
(1d)
Big Pharma Is Betting On LLMs and Agents. What Would Count As Success?
(4d)
Could Anthropic Disrupt the Techbio Companies Built for Pharma/Biotech?
(5d)
Is “Rescuing Failed Drugs with AI” a Category Now?
(5d)
Is the Future of AI Drug Discovery Hybrid?
(5d)
The Bigger Point Beyond Insilico's Aging Research Milestone
(2w)
The Measurement Challenge in Longevity: Can Aging Biomarkers and Clocks Close the Gap?
(2w)
What the New AI Model Releases by Anthropic and OpenAI Change for Life Sciences
(3w)
Into the Dark: Finding Novel Drug Targets Within the Depths of Our Proteome
(4w)
Beyond the Code: How DNA Nanotechnology is Moving from Molecular Origami to Programmable Biotech Platforms
(1mo)
Drug Channels
Why GoodRx Is Built for the AI-Driven Patient Journey
(13h)
The Spinoff: How Biosimilars Are Becoming Wholesalers' Next Hit Show
(3d)
Keep Your Patient Program at the Forefront of Innovation at Patient Pathways: The Copay and Patient Services Congress
(4d)
Fixing the Front Door Isn’t the Same as Fixing Time to Therapy
(1w)
Preorder DCI’s New 2026-27 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors
(1w)
Informa Connect’s Pharma/Biotech GTN Summit
(2w)
Drug Channels Leadership Forum 2027: Antonio Ciaccia to Serve as Moderator
(2w)
BlinkRx Insights: Beyond the Hub - Rethinking the Prescription Journey
(3w)
The Private Label Biosimilar Paradox in Medicare Part D
(3w)
Medicare, Medicaid, and Reverification: What Patient Support Programs Need to Know Before January 2027
(4w)
European Biotechnology Magazine
Bavarian Nordic names new CEO; Abivax and ProQR add key leaders
(15h)
Roche signs two deals worth about $3.5B in one day
(16h)
Nine pharma companies urge Europe to invest more in medicines
(1d)
Kasvu raises €30M for depression drug targeting TrkB
(1d)
Boehringer pays up to $250M to expand Variant Bio’s pact into heart disease
(1d)
Basecamp Research raises $140M for AI-designed cell therapies
(2d)
ViferaXS secures up to €12M for leukemia trial
(2d)
Scarlet gets $14M for smart red blood cells
(2d)
Roche hits Phase 3 IgAN endpoint but holds back data
(2d)
Cell therapies: breaking barriers in solid tumours
(3d)
Drug Hunter
QTX3034
(9h)
DAC 44
(1d)
Can Antibody Conjugation Offer a Path Forward for Genentech’s SMARCA2 Degraders?
(1d)
INCB161734
(2d)
ritonavir
(3d)
selgantolimod
(4d)
JNJ-2175
(1w)
AZD3632
(1w)
enpatoran (M5049)
(1w)
pociredir
(1w)
Labiotech.EU
Theialife’s race to bring a childhood myopia treatment to market
(15h)
“An open and collaborative culture”: what makes Sweden attractive for life sciences
(2d)
AstraZeneca’s pipeline strategy: building the next wave of growth
(3d)
How to navigate the IND process and shorten DNA-to-IND timelines to 6 months
(3d)
What can GLP-1s do beside treat diabetes and obesity?
(4d)
WCLC 2026: The lung cancer drug development readouts that caught our eye
(1w)
The best biotech conversations you missed this summer
(1w)
Oncology biotech news: key moves to watch in September 2026
(1w)
New non-opioid pain medication: How is the biotech industry fighting pain after the opioid crisis?
(1w)
BIOSPAIN 2026: Spain’s flagship biotech event is going annual
(1w)
Bio IT World
A Field in Transition: T Cell Engagers
(1d)
Elsevier, LG AI Research Integrate Chemistry-Specific AI Vision
(2d)
Apheris Announced the Results of their Federated Learning Co-Folding Initiative—Now Four Big Pharma Are Betting Bigger
(3d)
AI Can Help Find New Uses for Old Drugs; Advancing Them to Patients Is the Hard Part
(1w)
A 1970s Lipid-Lowering Compound May Offer a New Approach to Obesity
(1w)
Lehigh Team Uses Digital Twin of Gut-Brain Axis to Advance Neurostimulation Therapies
(1w)
What It Takes to Make Generative AI Fit for GMP
(2w)
Ultima, NVIDIA, Google Partner on Pangenome-Aware Whole Genome Sequencing
(2w)
Clearing the Bench-To-Bedside Hurdle: Why Translational Medicine Needs to Start Earlier
(3w)
NVIDIA Acquires Hugging Face for $12.93 Billion
(3w)
GEN News
Thar Process Partners with ExtrateX to Bring Prep to Process-Scale SFC to Europe
(5h)
How Bladder Cells Fight Hidden E. coli: New Insights Into Recurrent UTIs
(5h)
Stroke Remodels Tumor Microenvironment to Promote Glioma Growth
(7h)
New CRISPR-Based Tool Enables Genome-Wide Mutagenesis of Bacteriophages
(14h)
APOE4 Linked to Potentially Reversible Mechanisms of Brain Blood Vessel Damage in Alzheimer’s
(1d)
Muscle Cell Calcium Channel Structure, Synchronicity Could Advance Muscle Disease Therapeutics
(1d)
JNC Targets Bigger Molecules with Cellufine
(1d)
Intense Media Pressure an Emerging Challenge in CHO Business
(1d)
Altruist Biologics’ Suzhou Site Receives EMA GMP Certification
(1d)
New Liposome Design Could Provide Effective Slow-Release Drug Delivery System
(2d)
Cure Today
How Paxalisib Is Being Studied in Treatment-Resistant Breast Cancer
(3h)
Three August Blood Cancer Approvals and What They Mean for Care
(4h)
Walking Linked to 26% Lower Odds of Severe Fatigue After Colorectal Cancer
(6h)
How to Preserve Your Own Hair During Cancer Treatment
(7h)
Could a Genomic Test Spare You Extra Years of Hormone Therapy?
(9h)
We Eat Bagels Before Cancer Treatment. Here’s Why.
(10h)
What to Do Before Your Chemo Infusion: A Checklist From People Who've Been There
(1d)
How CAR-T Cell Therapy Is Changing Treatment for Childhood Leukemia
(1d)
FDA Approves Welireg Plus Lenvima for Advanced Kidney Cancer After Immunotherapy
(1d)
7 Breast Cancer Clinical Trials Currently Enrolling in the US
(1d)
Contract Pharma
Contract Pharma 2026 Conference Concludes with Risk Management Forum
(3h)
Reducing Product Loss in Sterile Manufacturing
(8h)
SK pharmteco Launches Catalyst Kit
(8h)
Recipharm, CanVirex Partner on Oncolytic Virus Manufacturing
(8h)
The Friday Brief for September 25, 2026: Live from Contract Pharma 2026
(9h)
Inside CPHI Milan’s New Sustainability Summit
(1d)
Cellares, SNUH Partner on Cell Therapy Manufacturing - contractpharma.com
(2d)
AustinPx KinetiSol Earns FDA AMT Designation - contractpharma.com
(2d)
Contract Pharma Announces New Bio Outsourcing Conference in Cambridge
(2d)
Astoriom Acquires Roylance Stability Storage and Roylance Scientific - contractpharma.com
(2d)
Pharma Times
Japan approves prefilled syringe for GSK’s shingles vaccine
(1w)
EpilepsyGTx and Viralgen partner to scale AAV manufacturing for EPY201
(1w)
Zerion partner files first EU application for Dispersome‑enabled product
(1w)
Tozorakimab shows broad COPD benefit in new phase 3 data
(1w)
Study highlights advance in influenza protection for older adults
(1w)
NICE backs daratumumab quadruplet for transplant‑eligible myeloma
(1w)
Teitur reports positive early data for Parkinson’s peptide TT‑P34
(2w)
Amivantamab regimen delivers longest survival in EGFR Ex20ins lung cancer
(2w)
NICE backs ibrutinib regimen for untreated mantle cell lymphoma
(2w)
Livdelzi accepted in Scotland for treatment of PBC
(2w)
Medcity News
Report: High Drug Costs Are Creating Hidden Burden for Physicians
(1h)
Gene Silencing-Biotech ADARx Makes Some Noise With $535M Stock Market Debut
(4h)
AI Goes All In To Support Nursing Teams: Ambient Charting is Just the Start
(10h)
UHC, Cigna and Centene Sign On to New National Shared Credentialing Program
(1d)
Lilly Again Looks to China for New Drugs, Paying InnoCare $100M to Start R&D Pact
(1d)
From OpenNotes to “Doc Can I Record You?” Why Physicians Should Embrace Era of Accountability
(1d)
Modernizing Medicare Advantage for the Next Generation of Seniors
(1d)
Phase 3 Data Could Make Roche Drug a Contender to Treat Rare Kidney Disease`
(2d)
Teal Health Secures $22M for At-Home HPV Cervical Cancer Screening Device
(2d)
Who is Abridge’s CEO Shiv Rao? No, Really…
(2d)
Chemical & Engineering News
BASF is in talks to buy Evonik
(4h)
At Climate Week, technology is still a solution to climate change
(6h)
Policy Watch: HHS and EPA move to coordinate on glyphosate review
(8h)
How wildfire smoke put Bordeaux’s wine at risk
(9h)
C&EN weekly chemistry news quiz, Sept. 25
(9h)
Wilfred A. van der Donk wins 2026 A. I. Scott Medal
(10h)
This battery is ready to eat
(1d)
Phosphate steps into new role as autonomous molecular machine
(1d)
Reading 2000-year-old scrolls without unfurling them
(1d)
Skeletal-editing ‘dream’ realized
(1d)
The Pharma Letter
Zenbexus doubles MRD-negative complete response rate in pivotal myeloma trial
(8h)
Nanexa soars on Novo deal for injection technology
(8h)
China expands role in manufacturing new FDA-approved drugs - thepharmaletter.com
(9h)
Merck’s Ogsiveo greenlighted by NICE - thepharmaletter.com
(9h)
Carvykti delivers five-year treatment-free remission in half of early-line myeloma patients - thepharmaletter.com
(9h)
Addex rises as it regains GABAB portfolio from Indivior
(11h)
Kyverna's miv-cel shows durable one-year benefit in stiff person syndrome and myasthenia gravis
(11h)
European Commission approves Nezglyal for rare brain disease
(11h)
FDA commissioner pick pledges to follow statutory requirements in FDA hearing
(11h)
FDA approves Welireg and Lenvima combo for advanced kidney cancer
(11h)
Targeted Oncology
Durvalumab-EV Perioperative Regimen Receives FDA Priority Review in MIBC
(3h)
Rethinking Transplant Eligibility in Multiple Myeloma in the MRD Era
(5h)
IMS 2026 Day 3 Recap: Etentamig Outperforms Standard Therapy in RRMM Trial
(6h)
Etentamig Shows Success With Focus on Tolerability, Administration in Relapsed Myeloma
(7h)
Etentamig Improves Response, PFS in Triple-Class Exposed Myeloma
(8h)
Biomarker Testing and Unmet Needs in Gastric/GEJ Cancers
(10h)
Annual Report Shows Continued Progress in US Cancer Outcomes
(10h)
Dr Hans Lee on New IMS/IMWG Criteria for Defining Cure in Myeloma
(1d)
FDA Approves Belzutifan Plus Lenvatinib for Advanced ccRCC
(1d)
FDA Panel Votes in Favor of Galleri Multi-Cancer Early Detection Test
(1d)
MedWatch
GSK reprimanded for lack of transparency in vaccine campaign case
(14h)
Low expectations could turn into an advantage for Novo in 2027, says Saxo strategist
(14h)
Nanexa deal shows Novo's appetite for new growth avenues, analyst says
(15h)
Hemab Therapeutics reshuffles board
(15h)
MSD’s eye drug meets primary endpoint in trial
(15h)
Roche pays Atavistik Bio USD 70m upfront in research partnership
(16h)
Lundbeck moves US headquarters to Boston and opens innovation hub
(16h)
Novo signs deal worth up to EUR 1.165bn with Sweden's Nanexa
(17h)
Scantox CFO steps down after acquisition spree, successor hired from outside
(1d)
Xellia returns to profit after years of heavy losses and strategic shift
(1d)
In The Pipeline
AI Help for Biological or Chemical Weapons
(1d)
As Close to Carbyne As We're Probably Going to Get
(2d)
tRNA Therapy
(3d)
Yet Another Attempt to Strangle Scientific Funding
(4d)
Safety Warning: Carborane Mixtures
(1w)
The Latest On CAR-T: Good and Bad
(1w)
The ACS Redesign
(1w)
Not The Glue They Thought It Was
(2w)
The State of AI Antibody Design
(2w)
Phosphorylate and Spare Not
(2w)
Pharmaphorum
EU clears first drug therapy for rare disease cALD
(11h)
FDA starts speedy review of Imfinzi in bladder cancer
(12h)
FDA nominee Overton dodges questions on Trump influence
(13h)
Wnt drug gives MSD first eye disease win after EyeBio deal
(15h)
Australia starts probe into AI infiltration of Medicare
(1d)
Lilly's rival to Novo's new Awiqli insulin gets FDA approval
(1d)
Kyverna builds case for CAR-T in stiff person syndrome
(1d)
Lilly forges $3.35bn alliance with China's InnoCare
(1d)
Grail cancer test gets lukewarm backing from FDA adcomm
(1d)
AI specialists Enveda and Basecamp rake in the cash
(2d)
Drug Discovery Weekly
Wegovy pill could help patients lose 17% body weight
(3mo)
How AskBio is pioneering ‘transformative genetic therapies’ in Parkinson’s disease
(3mo)
Webinar: Learn how to accelerate the early stages of drug discovery
(3mo)
Therapy enables 89% survival rate in myeloma patients
(3mo)
Ulcerative colitis treatment shows best-in-class potential
(3mo)
UK patients to benefit from approval of weight loss tablet
(3mo)
Vertex presents new data on Casgevy in children
(3mo)
DDW Highlights: 16 June 2026
(3mo)
LXR inverse agonist shows promise in liver disease
(3mo)
Guide: One solution – from R&D, to QC
(3mo)
HIT Consultant
Basalt Health Raises $20M to Scale Post-Acute AI Transition Platform Across 111 Markets
(1d)
CancerIQ Expands Native Epic Integrations to Automate Cancer Screening and Survivorship Across 275 Clinics
(1d)
Everlywell Appoints Chief Commercial and Product Officers to Expand Payer Diagnostic Care Platforms
(1d)
Hims Launches AI-Native Weight Loss Care Platform Featuring Closed-Loop Action Engine and Clinical Escalation
(1d)
Oracle Health Partners with ID.me to Embed Reusable Digital Identity Across Patient Portals and EPCS
(1d)
Trilliant Health Launches Oria AI Strategist to Replace Manual Healthcare Advisory
(1d)
Ensemble Health Partners with Penelope to Shift Real-Time Policy Intelligence Upstream
(1d)
America’s Elder-Care Crisis Has Arrived. We’re Not Ready.
(1d)
UltraSight Secures $24M to Scale Point-of-Care Cardiac Ultrasound Across Health Systems
(2d)
Vonage Brings Branded Calling to Epic Hello World to Drive 45% Patient Answer Rates
(2d)
Insights: Pink Sheet
Three Topics Dominated US FDA Commissioner Nominee Overton’s Senate Hearing
(1h)
Industry Pushes US FDA To Define ‘Highly Persuasive’ Single-Trial Bar
(2h)
Rosa Sherafat Takes Over US FDA Gene Therapy Clinical Review Office
(2h)
Another China Biotech Warning: Analysis Shows China Passes US In Oncology Approvals
(6h)
Pink Sheet Podcast: Lessons From US FDA Commissioner Nominee Heidi Overton’s Confirmation Hearing
(7h)
Recent And Upcoming US FDA Advisory Committee Meetings
(7h)
In Case You Missed It: GDUFA IV Deal Gives CMOs More Say, Defuses ‘Potential OAI’ Pain Point
(8h)
New EU Filings
(9h)
Will EU Pharma Reform Package Limit Appeal Of Smaller Markets In US MFN Era?
(9h)
UK To Close Regulatory Gaps With £20m Research Push
(10h)
BioXconomy
Sanofi’s regulatory leader breaks down ICH’s regulatory submission overhaul
(5h)
Avoiding the foul ball: Manufacturing siRNAs to improve patient adherence
(7h)
China's InnoCare lands up to $3.35bn Lilly deal
(9h)
How AI is streamlining patient support behind the scenes
(10h)
How AI is streamlining patient support behind the scenes
(10h)
Dispatches from CGT International: Big pharma M&A is the new biotech IPO
(14h)
The M&A paradox: Why signing the deal is just the beginning
(1d)
AI drug hunter Iambic files for Nasdaq IPO
(1d)
Kasvu raises $34m to develop alternative treatment for depression
(1d)
Trial management strategy outweighs service model in predicting study success
(2d)
BioCentury
Network Bio: Building disease-specific AI models with biobank data
(23h)
Enveda’s latest megaround puts $311M behind AI push: Venture Report
(1d)
Overton vows speed, deference to staff reviews, if confirmed to lead FDA
(1d)
How Europe’s VCs are chasing NewCo deals in China
(2d)
Amicus vet Campbell to succeed Dube as Travere CEO
(2d)
Science Spotlight: Degrading proteins without ubiquitin
(2d)
Led by the U.S. and China, radiopharma financing reaches new heights
(3d)
Tariff guidance leaves companies in the dark
(3d)
ShennonBio: Mining rare T cells for solid tumor therapies
(3d)
Beacon edges ahead in XLRP gene therapy race with Phase III hit
(4d)
SCRIP
Mirum’s Atebrioz, First Oral Approved For FOP, To Face Regeneron’s Pasatru
(2h)
Merck’s Withdrawal Of Recarbrio Takes It Off The Antibiotic Board
(2h)
Finance Watch: Big Money Keeps Flowing To AI-Enabled Drug Discovery And Development
(6h)
Mid-Sized Pharma And Lilly Setting M&A Pace In 2026
(7h)
The Eight Potential Immunological Blockbusters Coming To Market In 2027
(10h)
Executives On The Move: Jasper Therapeutics Bolsters Leadership After Kira Merger
(10h)
‘SNAC’ Bar: Novo Turns Up Heat In India Oral Semaglutide Patent Battle
(10h)
FDA Nod For Welireg-Lenvima Extends Merck’s Push Across The RCC Pathway
(11h)
Should Pharma Use Its PR Clout Against Climate Damage?
(13h)
Do API Exporters Really Need To Brace For The Sept. 29 Deadline Of US Tariffs?
(14h)